Skip to main content

Table 4 Change from pre-dose to 2 hours post dose in the functional impairment scale (each component and overall total score) - ITT set

From: A multicentre, randomised, double-blind, single-dose study assessing the efficacy of AMC/DCBA Warm lozenge or AMC/DCBA Cool lozenge in the relief of acute sore throat

 

AMC/DCBA

Warm lozenge

AMC/DCBA

Cool lozenge

Unflavoured,

non-medicated

lozenge

Talking

   

N

77

73

74

Mean ± SD

-1.09 ± 2.10

-0.56 ± 2.06

-0.20 ± 2.04

LS meana

-1.49

-0.99

-0.53

Parameter estimates

LS meanb

95% CI

P-value

AMC/DCBA Warm lozenge - unflavoured, non­medicated lozenges

-0.96

-1.59,-0.33

0.003 **

AMC/DCBA Cool lozenge - unflavoured, non­medicated lozenges

-0.46

-1.10,0.18

0.15

Swallowing

   

N

77

73

74

Mean ± SD

-1.35 ± 1.89

-1.36 ± 2.07

-0.65 ± 1.86

LS meana

-1.51

-1.57

-0.80

Parameter estimates

LS meanb

95% CI

P-value

AMC/DCBA Warm lozenge - unflavoured, non­medicated lozenges

-0.71

-1.30,-0.13

0.018 *

AMC/DCBA Cool lozenge - unflavoured, non­medicated lozenges

-0.77

-1.36,-0.17

0.011 *

Concentrating

   

N

77

73

74

Mean ± SD

-0.57 ± 1.82

-0.70 ± 1.83

-0.43 ± 1.28

LS meana

-0.86

-0.82

-0.63

Parameter estimates

LS meanb

95% CI

P-value

AMC/DCBA Warm lozenge - unflavoured, non­medicated lozenges

-0.23

-0.71,0.25

0.34

AMC/DCBA Warm lozenge - AMC/DCBA Cool lozenge

-0.19

-0.68,0.29

0.44

Reading

   

N

77

73

74

Mean ± SD

-0.21 ± 1.84

-0.41 ± 1.57

-0.22 ± 1.00

LS meana

-0.41

-0.54

-0.36

Parameter estimates

LS meanb

95% CI

P-value

AMC/DCBA Warm lozenge - unflavoured, non­medicated lozenge

-0.05

-0.49,0.39

0.82

AMC/DCBA Cool lozenge - unflavoured, non­medicated lozenge

-0.18

-0.63,0.27

0.43

TOTAL OF ALL FOUR RESPONSES

   

N

77

73

74

Mean ± SD

-3.2 ± 6.1

-3.0 ± 5.5

-1.5 ± 4.3

LS meana

-4.1

-3.8

-2.3

Parameter estimates

LS meanb

95% CI

P-value

AMC/DCBA Warm lozenge - unflavoured, non­medicated lozenge

-1.9

-3.6,-0.2

0.03 *

AMC/DCBA Cool lozenge - unflavoured, non­medicated lozenge

-1.5

-3.2,0.1

0.07

  1. a Estimated from ANCOVA model with factors for treatment and centre and covariates for baseline throat soreness and baseline score for the relevant variable.
  2. b A negative difference favours the first treatment against second treatment.
  3. * Significantly different compared with the unflavoured, non-medicated lozenge at the 5% level.
  4. CI, confidence interval; LS, least-squares; SD, standard deviation.
  5. Each activity measured on an 11-point scale where 0 = Would not interfere at all, 10 = Would completely interfere.